Loading
Cancer Research and Treatment / Hepatocellular Carcinoma Treatment and Prognosis / Liver Disease Diagnosis and Treatment · Journal article
Journal of Gastrointestinal Cancer · August 13, 2026
Encouraging direction, but not yet definitive.
This retrospective single-centre study of 86 HCC patients undergoing TARE identifies the ALBI score as the strongest independent predictor of overall survival (HR 3.70; p = 0.001 at 12 months), with OKUDA also significant, while conventional tumor burden scores showed limited prognostic value. The finding suggests hepatic functional reserve rather than tumor extent drives post-TARE outcomes, but requires prospective external validation before clinical adoption.
Retrospective single-centre cohort study. 86 patients with hepatocellular carcinoma and liver cirrhosis presenting for TARE; single centre; median age 67 years; predominant etiologies alcohol-related and metabolic dysfunction–associated steatotic liver disease.. Intervention: Transarterial radioembolization (TARE) for advanced HCC.. Compared with: No comparator; prognostic scoring systems evaluated within the same cohort.. n = 86. Single centre (location not specified in abstract)..
ALBI and OKUDA significantly associated with overall survival (HR 3.10, p < 0.001 and HR 5.02, p = 0.018 respectively) ALBI and CLIP showed highest predictive accuracy for 3-, 6-, and 12-month survival on ROC analysis ALBI and OKUDA remained independent predictors of 12-month survival in multivariable analysis (HR 3.70, p = 0.001 and HR 5.01, p = 0.025 respectively)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If confirmed prospectively, ALBI score assessment before and after TARE could improve patient selection and prognostic counselling in advanced HCC; the finding challenges reliance on tumor burden alone and emphasizes hepatic reserve as a primary determinant of locoregional therapy outcomes.
Single-centre retrospective study with modest sample size identifies ALBI score as prognostic for survival after TARE, but lacks prospective design, external validation, and mechanistic insight into clinical benefit.
As stated by the source record.
Quoted from the source exactly as published.
If confirmed prospectively, ALBI score assessment before and after TARE could improve patient selection and prognostic counselling in advanced HCC; the finding challenges reliance on tumor burden alone and emphasizes hepatic reserve as a primary determinant of locoregional therapy outcomes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Background Transarterial radioembolization (TARE) is an established locoregional therapy for advanced hepatocellular carcinoma (HCC). Prognosis depends on both tumor progression and hepatic function. Despite multiple scoring systems, predicting therapeutic benefit remains challenging. Materials and Methods This study evaluated the prognostic performance of established scores (BCLC, HAP, CLIP, OKUDA, ALBI, MELD, and Child-Pugh) for survival after TARE in 86 patients with HCC and liver cirrhosis. Predictive accuracy for 3-, 6-, and 12-month survival was assessed using ROC curve analyses. Results The median age was 67 years, and the predominant etiologies were alcohol-related and metabolic dysfunction–associated steatotic liver disease. Only ALBI and OKUDA were significantly associated with overall survival (HR 3.10; p < 0.001 and HR 5.02; p = 0.018, respectively). ALBI and CLIP showed the highest predictive accuracy for 3-, 6-, and 12-month survival. In multivariablee analysis, ALBI and OKUDA remained independent predictors of 12-month survival (HR 3.70; p = 0.001 and HR 5.01; p = 0.025, respectively). The ALBI score worsened significantly within 12 weeks after TARE ( p < 0.001). Conclusion The ALBI score was the strongest predictor of survival following TARE. In contrast, tumor burden showed limited prognostic relevance, underscoring hepatic functional reserve as a key determinant of outcomes after locoregional liver cancer therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.